Blueprint Medicines Corp (BPMC)
107.18
+1.72
(+1.63%)
USD |
NASDAQ |
May 15, 14:47
Blueprint Medicines Net Income (Quarterly): 89.14M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 89.14M |
December 31, 2023 | -110.92M |
September 30, 2023 | -133.71M |
June 30, 2023 | -132.79M |
March 31, 2023 | -129.56M |
December 31, 2022 | -158.65M |
September 30, 2022 | -133.16M |
June 30, 2022 | -159.71M |
March 31, 2022 | -106.00M |
December 31, 2021 | -318.69M |
September 30, 2021 | -117.24M |
June 30, 2021 | -108.44M |
March 31, 2021 | -99.71M |
December 31, 2020 | -85.67M |
September 30, 2020 | 633.98M |
June 30, 2020 | -123.47M |
March 31, 2020 | -110.96M |
December 31, 2019 | -66.33M |
September 30, 2019 | -94.28M |
June 30, 2019 | -99.68M |
March 31, 2019 | -87.41M |
Date | Value |
---|---|
December 31, 2018 | -80.32M |
September 30, 2018 | -72.72M |
June 30, 2018 | -27.05M |
March 31, 2018 | -56.55M |
December 31, 2017 | -49.03M |
September 30, 2017 | -37.70M |
June 30, 2017 | -33.41M |
March 31, 2017 | -27.98M |
December 31, 2016 | -21.26M |
September 30, 2016 | -16.83M |
June 30, 2016 | -18.89M |
March 31, 2016 | -15.50M |
December 31, 2015 | -15.58M |
September 30, 2015 | -12.64M |
June 30, 2015 | -12.98M |
March 31, 2015 | -11.57M |
December 31, 2014 | -14.47M |
September 30, 2014 | -10.50M |
June 30, 2014 | -8.287M |
March 31, 2014 | -7.027M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-318.69M
Minimum
Dec 2021
633.98M
Maximum
Sep 2020
-78.29M
Average
-110.94M
Median
Net Income (Quarterly) Benchmarks
Ligand Pharmaceuticals Inc | 86.14M |
Apellis Pharmaceuticals Inc | -66.42M |
Alnylam Pharmaceuticals Inc | -65.94M |
Biomarin Pharmaceutical Inc | 88.66M |
Corcept Therapeutics Inc | 27.76M |
Net Income (Quarterly) Related Metrics
Revenue (Quarterly) | 96.12M |
Total Expenses (Quarterly) | 174.94M |
EPS Diluted (Quarterly) | 1.40 |
Enterprise Value | 6.195B |
Gross Profit Margin (Quarterly) | 96.68% |
Profit Margin (Quarterly) | 92.74% |
Earnings Yield | -4.49% |
Normalized Earnings Yield | -7.022 |